These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24369125)

  • 1. Buy now, saved later? The critical impact of time-to-pandemic uncertainty on pandemic cost-effectiveness analyses.
    Drake T; Chalabi Z; Coker R
    Health Policy Plan; 2015 Feb; 30(1):100-10. PubMed ID: 24369125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs.
    Lugnér AK; Postma MJ
    Eur J Public Health; 2009 Oct; 19(5):516-20. PubMed ID: 19692550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investment in antiviral drugs: a real options approach.
    Attema AE; Lugnér AK; Feenstra TL
    Health Econ; 2010 Oct; 19(10):1240-54. PubMed ID: 19816857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Strategies for antiviral stockpiling for future influenza pandemics: a global epidemic-economic perspective.
    Carrasco LR; Lee VJ; Chen MI; Matchar DB; Thompson JP; Cook AR
    J R Soc Interface; 2011 Sep; 8(62):1307-13. PubMed ID: 21296791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral treatment for outpatient use during an influenza pandemic: a decision tree model of outcomes averted and cost-effectiveness.
    Venkatesan S; Carias C; Biggerstaff M; Campbell AP; Nguyen-Van-Tam JS; Kahn E; Myles PR; Meltzer MI
    J Public Health (Oxf); 2019 Jun; 41(2):379-390. PubMed ID: 29955851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methods for analyzing uncertainty].
    Ferriols R; Alós M
    Farm Hosp; 2011 May; 35 Suppl 2():3-9. PubMed ID: 22445503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of pharmaceutical-based pandemic influenza mitigation strategies.
    Newall AT; Wood JG; Oudin N; MacIntyre CR
    Emerg Infect Dis; 2010 Feb; 16(2):224-30. PubMed ID: 20113551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Cost-Effectiveness Analysis of a Pediatric Operating Room in Uganda.
    Yap A; Muzira A; Cheung M; Healy J; Kakembo N; Kisa P; Cunningham D; Youngson G; Sekabira J; Yaesoubi R; Ozgediz D
    Surgery; 2018 Nov; 164(5):953-959. PubMed ID: 29801729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Value for Money in H1N1 Influenza: A Systematic Review of the Cost-Effectiveness of Pandemic Interventions.
    Pasquini-Descomps H; Brender N; Maradan D
    Value Health; 2017 Jun; 20(6):819-827. PubMed ID: 28577700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evidence synthesis, parameter correlation and probabilistic sensitivity analysis.
    Ades AE; Claxton K; Sculpher M
    Health Econ; 2006 Apr; 15(4):373-81. PubMed ID: 16389628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis of orthoptic screening in kindergarten: a Markov model based on data from Germany.
    König HH; Barry JC
    Pediatrics; 2004 Feb; 113(2):e95-108. PubMed ID: 14754978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of palivizumab for respiratory syncytial virus prophylaxis in premature infants with a gestational age of 32-35 weeks: a Canadian-based analysis .
    Lanctôt KL; Masoud ST; Paes BA; Tarride JE; Chiu A; Hui C; Francis PL; Oh PI
    Curr Med Res Opin; 2008 Nov; 24(11):3223-37. PubMed ID: 18928643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
    Kim SY; Lee G; Goldie SJ
    BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economics of neuraminidase inhibitor stock piling for pandemic influenza, Singapore.
    Lee VJ; Phua KH; Chenm MI; Chow A; Ma S; Goh KT; Leo YS
    Emerg Infect Dis; 2006 Jan; 12(1):95-102. PubMed ID: 16494724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness and return on investment of protecting health workers in low- and middle-income countries during the COVID-19 pandemic.
    Risko N; Werner K; Offorjebe OA; Vecino-Ortiz AI; Wallis LA; Razzak J
    PLoS One; 2020; 15(10):e0240503. PubMed ID: 33035244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method.
    Hunink MG; Bult JR; de Vries J; Weinstein MC
    Med Decis Making; 1998; 18(3):337-46. PubMed ID: 9679999
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa: a probabilistic decision model.
    Uthman OA; Popoola TA; Yahaya I; Uthman MM; Aremu O
    Value Health; 2011 Jan; 14(1):70-9. PubMed ID: 21211488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.